Published in Clin Cancer Res on August 15, 2005
Development of cell-cycle inhibitors for cancer therapy. Curr Oncol (2009) 1.57
Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology (2007) 1.48
Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs (2011) 1.39
The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol (2011) 1.39
Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage. Retrovirology (2009) 1.17
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.12
Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets (2010) 1.10
Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res (2011) 1.01
New combination therapies with cell-cycle agents. Curr Opin Investig Drugs (2008) 0.98
Turning the gene tap off; implications of regulating gene expression for cancer therapeutics. Mol Cancer Ther (2008) 0.94
Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. Invest New Drugs (2009) 0.93
Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer. Oncotarget (2015) 0.90
Organometallic 3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines as potential anticancer agents. Inorg Chem (2011) 0.89
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol (2010) 0.88
A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecol Oncol (2012) 0.87
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer (2012) 0.86
A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model. Br J Radiol (2009) 0.79
Zebrafish as a model system to screen radiation modifiers. Curr Genomics (2007) 0.78
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc (2008) 8.94
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
PARP inhibition: PARP1 and beyond. Nat Rev Cancer (2010) 6.70
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol (2004) 6.61
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin (2005) 4.06
Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology (2007) 3.85
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol (2010) 3.75
Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest (2005) 3.51
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol (2005) 3.41
Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol (2006) 3.31
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer (2007) 3.28
Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology (2007) 3.08
Small cell lung cancer. Mayo Clin Proc (2008) 2.99
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg (2003) 2.88
Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res (2008) 2.76
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol (2005) 2.65
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res (2007) 2.61
Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol (2010) 2.57
Factors associated with progression of carcinoid heart disease. N Engl J Med (2003) 2.57
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol (2005) 2.56
Pathophysiology and treatment of hot flashes. Mayo Clin Proc (2002) 2.56
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A (2011) 2.47
Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem (2003) 2.40
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol (2005) 2.32
Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. J Natl Cancer Inst (2007) 2.31
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res (2005) 2.29
Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol (2010) 2.28
Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. J Clin Oncol (2006) 2.22
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res (2008) 2.20
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res (2010) 2.19
Novel agents on the horizon for cancer therapy. CA Cancer J Clin (2009) 2.11
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res (2011) 2.08
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol (2009) 2.06
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol (2008) 2.06
Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer (2008) 2.04
Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03
BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res (2008) 2.03
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol (2011) 2.03
Advances in chemotherapy of non-small cell lung cancer. Chest (2006) 2.00
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res (2004) 1.91
Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol (2004) 1.90
Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology (2008) 1.87
Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res (2012) 1.87
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood (2009) 1.86
Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis (2012) 1.84
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol (2006) 1.84
Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. EMBO J (2002) 1.82
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer (2008) 1.80
A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab (2012) 1.80
Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation. Radiology (2002) 1.79
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol (2008) 1.77
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res (2006) 1.75
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol (2008) 1.75
K-ras as a target for cancer therapy. Biochim Biophys Acta (2005) 1.74
Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. J Cell Biol (2011) 1.73
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res (2002) 1.72
S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem (2001) 1.72
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res (2009) 1.71
MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol (2012) 1.71
Human aromatase: gene resequencing and functional genomics. Cancer Res (2005) 1.71
Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol (2006) 1.70
Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem (2007) 1.63
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res (2007) 1.61
Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol (2005) 1.61
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood (2006) 1.59
Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila) (2011) 1.57
The well-being and personal wellness promotion strategies of medical oncologists in the North Central Cancer Treatment Group. Oncology (2005) 1.57
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2008) 1.56
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood (2011) 1.56
Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin (2013) 1.54
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol (2003) 1.54
Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation (2005) 1.53
Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One (2011) 1.53
A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res (2006) 1.51
Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem (2007) 1.51
Farnesyltransferase inhibitors. Semin Oncol (2004) 1.48
Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res (2009) 1.48